Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis.

Familial cancer - 1 Jan 2006

Foulkes William D

Abstract excerpt

BRCA1 and BRCA2 are important breast and ovarian cancer susceptibility genes, and mutations in these two genes confer lifetime risks of breast cancer of up to 80% and ovarian cancer risks of up to 40%. Clinico-pathological studies have identified features that are specific to BRCA1-related breast...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to DNA Methylation
Share to Genes, BRCA1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA2

Share to Mutation

Share to Ovarian Neoplasms

Share to Prognosis

Share to Treatment Outcome

Source

Identifiers

PMID: 16736282
DOI: 10.1007/s10689-005-2832-5

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-16736282-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis.PMID 16736282Read ↗

Hereditary ovarian cancer: biology, response to chemotherapy and prognosis.Semantic proximity Read ↗

Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypesSemantic proximity Read ↗

The clinical features associated with mutated BRCA1 and 2 genes in ovarian cancer patients.Semantic proximity Read ↗

In brief: BRCA1 and BRCA2.Semantic proximity Read ↗

Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different?Semantic proximity Read ↗

BRCA1/2 testing: therapeutic implications for breast cancer managementSemantic proximity Read ↗

Hereditary breast and ovarian cancer: new genes, new treatments, new concepts.Semantic proximity Read ↗

BRCA1 and BRCA2 mutations and breast cancer.Semantic proximity Read ↗

BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patientsSemantic proximity Read ↗

Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1and BRCA2mutation carriers.Semantic proximity Read ↗

Study finds different treatment responses between BRCA2- and BRCA1-mutated ovarian cancers.Semantic proximity Read ↗

Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.